Is Coxsackievirus Dangerous for Pregnant Women?

Coxsackievirus can pose serious risks during pregnancy, though the vast majority of infections in pregnant women are mild or go unnoticed entirely. The danger lies in what happens when the virus crosses the placenta: vertical transmission has been linked to miscarriage, congenital heart defects, severe neonatal illness, and, in rare cases, fetal or newborn death. The overall picture is more complicated than a simple yes-or-no, because the timing of infection, the specific virus strain, and whether symptoms appear at all can dramatically shift the outcome.

What Coxsackievirus Actually Is

Coxsackievirus belongs to the enterovirus family and comes in two main groups: A and B. Group B strains (CVB1 through CVB6) are the ones most studied in pregnancy, and they tend to be the bigger concern for fetal and neonatal health. The virus spreads primarily through the fecal-oral route, meaning contact with contaminated surfaces, food, or water, and also through respiratory droplets. Infections peak during warmer months, roughly the third quarter of the year in temperate climates.

In non-pregnant adults, coxsackievirus usually causes a short-lived illness: a fever, sore throat, maybe some muscle aches. Many people who catch it never realize they are sick at all. That ordinariness is part of what makes it tricky in pregnancy. A virus that barely registers as a cold can quietly reach the fetus and cause damage that is out of proportion to how the mother feels.

How the Virus Reaches the Fetus

The placenta is supposed to act as a barrier, and for most infections it does a good job. Coxsackievirus B, however, has found ways around that barrier. The virus binds to a receptor on the surface of placental cells called decay-accelerating factor, then relocates to the tight junctions between cells. From there, it uses a pathway that depends on structures in the cell membrane known as lipid rafts, along with a family of signaling enzymes, to get inside placental tissue.

1PubMed Central. Lipid raft- and SRC family kinase-dependent entry of coxsackievirus B into human placental trophoblasts

Once inside the placenta, the virus can reach the fetal bloodstream. This vertical transmission is considered rare, but when it does happen, the consequences range from subclinical infection in the baby to life-threatening organ damage. A key challenge is that many maternal infections are completely asymptomatic, so neither the mother nor her doctor may realize transmission has occurred until the newborn becomes ill.

2PubMed. Coxsackie Virus A16 Infection of Placenta with Massive Perivillous Fibrin Deposition Leading to Intrauterine Fetal Demise at 36 Weeks Gestation

Early Pregnancy and Miscarriage

Infection in the first trimester carries a distinct set of risks. A Korean study examined placental and fetal tissue from women who experienced missed abortions (pregnancies that stop developing but are not immediately expelled) and found coxsackievirus B3 in more than half of the missed-abortion cases, compared to a small fraction of normal full-term pregnancies. The researchers concluded that CVB infection could be an important cause of early pregnancy loss.

3PubMed Central. Coxsackievirus B infection is highly related with missed abortion in Korea

This does not mean every coxsackievirus infection in early pregnancy leads to miscarriage. One older survey tracked fourteen pregnant women who had confirmed enterovirus infections between 16 and 37 weeks of gestation, including four with meningitis, and all of them delivered healthy, uninfected infants.

4American Journal of Obstetrics and Gynecology. Enterovirus in pregnant women and the perfused placenta

The difference seems to come down to whether the virus actually crosses the placenta and establishes infection in fetal tissue. When it does not, the pregnancy can proceed normally. When it does, the first trimester is a particularly vulnerable window because critical organ systems are still forming.

Congenital Heart Defects

Perhaps the most alarming finding in recent research involves the heart. Animal studies have shown that coxsackievirus B3 infection during early pregnancy can cause structural heart defects in the developing fetus. In one study, among over 200 viable fetuses from infected animals, roughly a third had ventricular septal defects (holes between the heart chambers), about a quarter showed abnormal heart muscle architecture resembling a condition called noncompaction, and a smaller percentage had a defect known as double-outlet right ventricle.

5PubMed Central. Coxsackievirus B3 Infection Early in Pregnancy Induces Congenital Heart Defects Through Suppression of Fetal Cardiomyocyte Proliferation

The mechanism appears to involve the virus interfering with the normal multiplication of heart muscle cells during development. When those cells cannot proliferate on schedule, the heart’s internal walls and chambers do not form properly. And it is not just one strain: research has found that CVB1, CVB4, and co-infections with multiple strains can all produce similar defects, with co-infection rates pushing the proportion of affected fetuses above half in experimental models.

6PubMed. Multiple subtypes of coxsackievirus group B can cause congenital heart disease

These findings come primarily from animal models, so translating the exact percentages to human pregnancies is not straightforward. But the biological pathway is concerning enough that researchers view prenatal coxsackievirus infection as a plausible contributor to some unexplained congenital heart defects in humans. The critical window appears to be early pregnancy, when the heart is undergoing rapid structural development.

Severe Fetal and Neonatal Disease

When the virus reaches a fetus or newborn later in pregnancy, the damage tends to look different. Instead of structural birth defects, the concern shifts to acute organ inflammation. Coxsackievirus B has a particular affinity for heart muscle and brain tissue. Case reports have documented fetal hydrops (dangerous fluid accumulation) caused by CVB4 at 22 weeks, as well as fatal neonatal cases involving myocarditis, encephalitis with brain tissue destruction, and inflammation of the spinal cord membranes and liver.

7PubMed Central. Antenatal and Postnatal Diagnosis of Coxsackie B4 Infection: Case Series

Another documented case involved a fetus with fetal akinesia deformation sequence, a condition where the baby stops moving normally in the womb, resulting in joint contractures and other abnormalities. At autopsy, findings included severe brain inflammation with vascular calcifications, lung inflammation, and chronic inflammation of the placenta itself.

8PubMed. Transplacental infection of Coxsackievirus B3 pathological findings in the fetus

These cases are rare, but they illustrate why coxsackievirus is taken seriously in perinatal medicine. The newborns at greatest risk are those infected shortly before or during birth, because they have no maternal antibodies to buffer the infection. Babies born to mothers with acute infection right around delivery can become critically ill within days.

What Happened in Northern Ireland

A real-world cluster in Northern Ireland between late 2024 and early 2025 underscores how severe neonatal coxsackievirus can be. Four newborns, all younger than 18 days old, were hospitalized with confirmed coxsackievirus B4 infections. Three developed meningitis. One deteriorated rapidly, progressing to sepsis, multi-organ failure, and death at six days of life. Two of the four were classified as congenital infections, meaning they were likely infected before birth, with one baby already symptomatic at delivery.

9PubMed Central. Coxsackievirus B4 linked to four severe neonatal infections including one fatal, Northern Ireland, October 2024 to February 2025

Clusters like this tend to draw attention to a virus that otherwise flies under the radar. Unlike cytomegalovirus or Zika, which have established screening and awareness campaigns, coxsackievirus is not routinely tested for during pregnancy. There is no vaccine and no antiviral treatment approved specifically for it. When outbreaks occur, the public health response is largely reactive.

The Problem of Silent Infections

One of the most frustrating aspects of coxsackievirus in pregnancy is that the mother may have no symptoms at all. The virus can circulate in the bloodstream, reach the placenta, and infect the fetus without the pregnant person ever feeling unwell. This makes clinical detection extremely difficult. Doctors cannot screen for something they have no reason to suspect.

10PubMed Central. Coxsackievirus Group B Infections during Pregnancy: An Updated Literature Review

Even when a pregnant woman does have symptoms, they often mimic a common cold or a mild stomach bug. Fever, fatigue, a rash, or a few days of nausea are easy to dismiss. Specific testing for enteroviruses, such as RT-PCR on blood or amniotic fluid, is available but is not part of routine prenatal care. It is typically ordered only when a newborn turns up sick and doctors work backward to identify the cause.

This gap between the virus’s potential severity and the lack of routine detection is a central tension in the research. Multiple review papers have described coxsackievirus vertical transmission as “underestimated” and “neglected,” pointing out that the true burden of pregnancy-related infections is almost certainly higher than reported case counts suggest.

11PubMed. Vertical Transmission of Type B Coxsackieviruses: A Systematic Review Emphasising Clinical Evidence and Seriousness of a Neglected Issue

Long-Term Health Effects on the Child

Beyond the immediate risks of miscarriage, birth defects, and neonatal illness, researchers have explored whether prenatal coxsackievirus exposure might contribute to long-term health problems, particularly type 1 diabetes. The hypothesis has been around for decades: coxsackievirus B infects the pancreas and could, in theory, trigger an autoimmune process that eventually destroys insulin-producing cells.

The evidence here is genuinely mixed, and researchers have gone back and forth on it. One study found that mothers whose children later developed type 1 diabetes were significantly more likely to have had antibodies against coxsackievirus B3 at delivery, with an estimated odds ratio of about 2.5. The researchers calculated that roughly a quarter of childhood diabetes cases in their study population could be attributable to this exposure.

12PubMed. Indications that maternal coxsackie B virus infection during pregnancy is a risk factor for childhood-onset IDDM

However, a larger study looking specifically at first-trimester enterovirus infections found no significant difference in antibody levels between mothers of children who developed diabetes and control mothers. Enterovirus RNA was detected in fewer than 1% of the sampled cases. The authors concluded that first-trimester enterovirus infection did not appear to increase the risk of type 1 diabetes in the child.

13Diabetes. Maternal First-Trimester Enterovirus Infection and Future Risk of Type 1 Diabetes in the Exposed Fetus

The discrepancy may come down to timing (first trimester versus near delivery), the specific viral strain, or differences in study design. The diabetes connection remains an open question in the field rather than an established fact. What is clear is that coxsackievirus B has a tropism for the pancreas in addition to the heart and brain, which keeps the hypothesis alive even if the epidemiological evidence has not settled it.

What You Can Do to Reduce Risk

Without a vaccine or antiviral, prevention comes down to avoiding the virus in the first place. That is easier said than done for a pathogen spread through fecal-oral and respiratory routes, but the basics of hygiene make a real difference:

  • Hand hygiene: Wash your hands thoroughly with soap and water after using the bathroom, changing diapers, and before eating or preparing food. Alcohol-based sanitizers work against many pathogens but are less effective against non-enveloped viruses like enteroviruses.
  • Avoid sick contacts: If a child in your household or workplace has hand, foot, and mouth disease or an unexplained fever with rash, limit close contact and be meticulous about cleaning shared surfaces.
  • Seasonal awareness: Coxsackievirus infections spike in summer and early fall. Extra vigilance during these months is reasonable, especially if you are in the first trimester.
  • Swimming and water safety: Enteroviruses can survive in recreational water. Avoid swallowing pool or lake water, and choose well-maintained, properly chlorinated facilities.

If you develop a febrile illness during pregnancy that includes symptoms like chest pain, a distinctive rash (particularly on the hands, feet, or mouth), or muscle tenderness, mention the possibility of enterovirus to your healthcare provider. While routine testing is not standard, targeted testing can be done when clinical suspicion is present, and early awareness could influence monitoring of the newborn after delivery.

Why This Virus Gets Less Attention Than Others

Pregnant women hear a lot about certain infections: Zika, cytomegalovirus, toxoplasmosis, rubella, listeria. Coxsackievirus rarely makes that list, despite evidence that its potential consequences overlap with some of those better-known threats. There are a few reasons for this gap.

First, severe outcomes from coxsackievirus in pregnancy are relatively uncommon. Most pregnant women who catch it will never know, and most of those whose babies are exposed will have healthy deliveries. The rarity makes it hard to build large-scale studies and harder still to justify adding it to routine screening panels. Second, there is no intervention available even if you do detect it. With rubella, there is a vaccine. With toxoplasmosis, there are antibiotics. With coxsackievirus, diagnosis does not change treatment in most cases, which reduces the incentive to screen. Third, the virus family is enormous. Enteroviruses include dozens of serotypes, and building immunity or a vaccine against one does not protect against the others.

Researchers have been pushing for more attention to this area. A 2025 systematic review explicitly framed coxsackievirus B vertical transmission as a “neglected issue,” arguing that the clinical evidence is serious enough to warrant better surveillance and more investment in antiviral development.

11PubMed. Vertical Transmission of Type B Coxsackieviruses: A Systematic Review Emphasising Clinical Evidence and Seriousness of a Neglected Issue

When the Timing of Infection Matters Most

The risks from coxsackievirus are not uniform across pregnancy. The evidence points to two particularly sensitive windows. The first is early pregnancy, roughly the period of organ formation. This is when congenital heart defects and early pregnancy loss are most likely if the virus reaches the fetus. The animal data showing ventricular septal defects and abnormal heart architecture consistently ties the damage to early gestational exposure.

The second high-risk window is the days immediately surrounding delivery. A baby born to a mother with active viremia (virus circulating in her blood) may be infected during birth and will not yet have the immune resources to fight it off. Neonates lack the mature immune defenses that older children use to clear enteroviruses quickly, and they have not had time to receive protective antibodies through breastmilk. The Northern Ireland cluster is a stark example: infants who were likely infected at or just before birth became dangerously ill within days.

The middle stretch of pregnancy appears to be somewhat lower risk, though it is not risk-free. Cases of fetal hydrops, intrauterine growth restriction, and stillbirth have been reported in the second and third trimesters as well. The overall pattern seems to be that the virus is always capable of harm if it reaches the fetus, but the type and severity of harm depend on the developmental stage at the time of infection.

Vaccine and Treatment Research

Several research groups are working on enterovirus vaccines, though none is yet approved for use in humans. The challenge is the diversity of the enterovirus family. A vaccine targeting CVB3 would not protect against CVB1, CVB4, or the dozens of coxsackievirus A strains. Some experimental multivalent approaches aim to cover multiple strains at once, but these are still in preclinical or early clinical stages.

On the treatment side, a few antiviral compounds have shown activity against enteroviruses in laboratory settings, including pleconaril and pocapavir, but their use in pregnant women has not been studied in clinical trials. For now, the management of a confirmed neonatal coxsackievirus infection is supportive: intensive care for organ failure, cardiac monitoring, and in severe cases, intravenous immunoglobulin, though evidence for its effectiveness against enteroviruses specifically is limited. The absence of proven therapeutics is a major reason why prevention through basic hygiene remains the only practical recommendation for pregnant women. If the research landscape changes and effective antivirals or vaccines reach clinical use, the entire calculus around screening and early detection would likely shift with it.